Esperion Therapeutics Inc. (ESPR)
$3.14
$0.01
(0.16%)
As on 05-Jun-2026 13:41EDT
Market cap
$806 Mln
Revenue (TTM)
$418 Mln
P/E Ratio
--
P/B Ratio
98.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.6 %
-
ROCE
-- %
-
Industry P/E
30.2
-
EV/EBITDA
11.3
-
Debt to Equity
-0.8
-
Book Value
$--
-
EPS
$-0.1
-
Face value
--
-
Shares outstanding
257,431,942
10 Years Aggregate
CFO
$-1,127.49 Mln
EBITDA
$-1,296.01 Mln
Net Profit
$-1,621.04 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Esperion Therapeutics (ESPR)
| -15.3 | 0.5 | 7.7 | 179.9 | 32.1 | -31.5 | -15.5 |
|
BSE Sensex
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Esperion Therapeutics (ESPR)
| 68.2 | -26.2 | -52.0 | 24.6 | -80.8 | -56.4 | 29.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Esperion Therapeutics (ESPR)
|
3.1 | 805.8 | 418.2 | -7.4 | 18.4 | -- | -- | 98.4 |
| 41.0 | 5,252.7 | 1,105.3 | 133.3 | 15.9 | 32.7 | 38.3 | 12.7 | |
| 241.3 | 12,066.3 | 708.2 | -188.3 | -25.6 | -293.5 | -- | 221.1 | |
| 68.0 | 12,977.8 | 580.0 | -725.9 | -105.2 | -- | -- | 123.7 | |
| 73.9 | 7,459.9 | 769.1 | 47.9 | 5.4 | 7.5 | 198.5 | 11.2 | |
| 13.3 | 11,337.9 | 353,471.6 | 45,087.2 | 16.1 | 12.8 | 25.6 | 2.9 | |
| 23.8 | 11,832.0 | 4,893.0 | -242.0 | -1.5 | -3.7 | -- | 1.8 | |
| 7.6 | 5,342.5 | 7,447.6 | 415.6 | 16.2 | 6.6 | 11.1 | 0.9 | |
| 238.4 | 4,648.7 | 274.5 | 153.6 | 76.6 | 15.8 | 30.2 | 4.7 | |
| 62.1 | 5,501.1 | 288.1 | 22.3 | 17.5 | 34.1 | 363.9 | 50.5 |
Shareholding Pattern
View DetailsAbout Esperion Therapeutics (ESPR)
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include... NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Read more
-
President, CEO & Director
Mr. Sheldon L. Koenig
-
President, CEO & Director
Mr. Sheldon L. Koenig
-
Headquarters
Ann Arbor, MI
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Esperion Therapeutics (ESPR)
What is the current share price of Esperion Therapeutics Inc (ESPR) Today?
The share price of Esperion Therapeutics Inc (ESPR) is $3.14 (NASDAQ) as of 05-Jun-2026 13:41 EDT. Esperion Therapeutics Inc (ESPR) has given a return of 32.1% in the last 3 years.
What is the current PB & PE ratio of Esperion Therapeutics Inc (ESPR)?
Since, TTM earnings of Esperion Therapeutics Inc (ESPR) is negative, P/E ratio is not available.
The P/B ratio of Esperion Therapeutics Inc (ESPR) is 98.42 times as on 29-May-2026, a 1565 premium to its peers’ median range of 5.91 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-46.42
|
-3.49
|
|
2024
|
-8.31
|
-1.11
|
|
2023
|
-1.61
|
-0.74
|
|
2022
|
-1.96
|
-1.41
|
|
2021
|
-0.68
|
-0.94
|
What is the 52 Week High and Low of Esperion Therapeutics Inc (ESPR)?
The 52-week high and low of Esperion Therapeutics Inc (ESPR) are Rs 4.18 and Rs 0.95 as of 06-Jun-2026.
What is the market cap of Esperion Therapeutics Inc (ESPR)?
Esperion Therapeutics Inc (ESPR) has a market capitalisation of $ 806 Mln as on 29-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Esperion Therapeutics Inc (ESPR)?
Before investing in Esperion Therapeutics Inc (ESPR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.